A proposal of new therapeutic strategy for antenatally diagnosed congenital diaphragmatic hernia

J Pediatr Surg. 2005 Aug;40(8):1315-9. doi: 10.1016/j.jpedsurg.2005.05.018.

Abstract

Purpose: The prognosis of antenatally diagnosed congenital diaphragmatic hernia (ADCDH) is still very poor despite of innovation of various therapeutics. The authors reviewed their new therapeutic strategy of ADCDH from a viewpoint of cardiologic function.

Methods: The cardiac function in 19 cases of ADCDH was reviewed. The patients, at the age of 0 days, were divided into 2 groups, PG (+) and PG (-), according to the requirement of prostaglandin E1 (PGE1) to attenuate pulmonary hypertension. The left ventricular (LV) end-diastolic dimension (LV diastolic diameter index [LVDI]) and bilateral pulmonary arterial diameters (total pulmonary artery index [TPAI]) were measured on days 0 and 2.

Result: Only 1 patient died of cardiac or respiratory failure, and the survivors' postoperative course was uneventful. Eleven patients needed inhalation of nitric oxide (NO), and in 9 of those, PGE1 was administered. The LVDI and TPAI of day 0 in PG (+) were significantly smaller than those in PG (-) and the controls. The LVDI increased from postnatal day 0 to day 2 in both PG (+) and PG (-). Although the LV was too small to output enough volume, the right ventricle successfully compensated for the low output through the ductus arteriosus, kept patent by NO and PGE1.

Conclusion: For ADCDH with sever pulmonary hypertension, keeping patent ductus arteriosus with NO and PGE1 plays a critical role in obtaining excellent clinical outcome. Thus, the authors proposed a new therapeutic strategy for ADCDH based on a circulatory management.

MeSH terms

  • Alprostadil / pharmacology
  • Alprostadil / therapeutic use
  • Ductus Arteriosus / drug effects*
  • Ductus Arteriosus / physiology
  • Echocardiography
  • Female
  • Hernia, Diaphragmatic / complications
  • Hernia, Diaphragmatic / diagnostic imaging
  • Hernia, Diaphragmatic / therapy*
  • Hernias, Diaphragmatic, Congenital*
  • Humans
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / prevention & control
  • Infant, Newborn
  • Nitric Oxide / pharmacology
  • Nitric Oxide / therapeutic use*
  • Persistent Fetal Circulation Syndrome / etiology
  • Persistent Fetal Circulation Syndrome / physiopathology*
  • Pregnancy
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / pathology
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Respiratory Distress Syndrome, Newborn / etiology
  • Ultrasonography, Prenatal
  • Vasodilator Agents / therapeutic use
  • Ventricular Dysfunction / physiopathology

Substances

  • Vasodilator Agents
  • Nitric Oxide
  • Alprostadil